Data from the in vitro study further suggested that the efficacy of DR17 treatment resulted, in part, from the targeting of multiple prostate cancer relevant signaling pathways including PI3K/AKT/mTOR and HSP90/HSP70/AR. This evidence concerns the gene AKT1 and prostate carcinoma.